These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30724992)

  • 1. [New cephalosporins].
    Olarte-Luis T; Cáceres-Galíndez D; Cortés JA
    Rev Chilena Infectol; 2018; 35(5):465-475. PubMed ID: 30724992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
    Rando E; Novy E; Sangiorgi F; De Pascale G; Fantoni M; Murri R; Roberts JA; Cotta MO
    Int J Antimicrob Agents; 2024 Sep; 64(3):107266. PubMed ID: 38971203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2020 Mar; 96(3):114833. PubMed ID: 31924426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
    Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trials.
    Avilés Martínez MC; Alfaro Martínez JJ; Blanch Sancho JJ; Solís García Del Pozo J
    J Chemother; 2022 Nov; 34(7):419-426. PubMed ID: 35550007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
    Gatti M; Raschi E; De Ponti F
    Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1169-1176. PubMed ID: 33415492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
    Chumbita M; Monzo-Gallo P; Lopera-Mármol C; Aiello TF; Puerta-Alcalde P; Garcia-Vidal C
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):51-53. PubMed ID: 36285859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.